Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)

NCT00364286 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Lymphoma

Interventions

DRUG: Dasatinib (BMS-354825)

Sponsor

M.D. Anderson Cancer Center

Collaborators

Bristol-Myers Squibb